Tokyo Tape
Sign in
← Jmdc

Quarterly report · Q2

4483.TEDINET S100PLQM
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥12.1bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥6.3bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥21.8bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥9.6bn2021-04-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥5.0bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥2.2bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥1.1bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥1.7bn2021-04-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥909m2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥2.2bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.1bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥4.8bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥1.7bn2021-04-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥908m2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥678m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥3.2bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.1bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥597m2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥677m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥1.1bn2021-04-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥598m2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥112.1bnat 2022-09-30Cons.Assets IFRS
Total assets¥62.1bnat 2022-03-31Cons.Assets IFRS
Total assets¥58.1bnat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥50.5bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥30.9bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥61.6bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥31.2bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥28.9bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥28.3bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥61.6bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥31.2bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥28.9bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥41.5bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.2bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥15.5bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.9bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥1.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥3.8bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.1bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥21.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥8.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥3.8bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥48.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥2.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.7bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥25.292022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥11.762022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥57.742021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥20.262021-04-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥10.642021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥23.862022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥11.142022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥54.162021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥19.062021-04-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥102021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio55.0%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio50.2%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio49.8%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 72
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥126m
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥67m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥126m
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥67m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥189m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30−¥99m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-07-01 → 2022-09-30¥933m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-07-01 → 2022-09-30¥890m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥84m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥42m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-04-01 → 2022-09-30¥192m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-07-01 → 2022-09-30¥144m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2022-07-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-07-01 → 2022-09-30¥4.1bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥42m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥24m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-04-01 → 2022-09-30¥2.0bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-07-01 → 2022-09-30¥903m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2022-04-01 → 2022-09-30¥2.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2022-07-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2022-04-01 → 2022-09-30¥2.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2022-07-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2022-04-01 → 2022-09-30¥924m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2022-07-01 → 2022-09-30¥485m
—segment totalrevenue2022-04-01 → 2022-09-30¥12.2bn
—segment totalrevenue2022-07-01 → 2022-09-30¥6.4bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥12.1bn
—segment totalrevenue external2022-07-01 → 2022-09-30¥6.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥126m
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥67m
—segment totalsegment profit2022-04-01 → 2022-09-30¥3.1bn
—segment totalsegment profit2022-07-01 → 2022-09-30¥1.5bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥88m
Reconciling Itemsreconcilingrevenue2021-07-01 → 2021-09-30−¥53m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥88m
Reconciling Itemsreconcilingrevenue intersegment2021-07-01 → 2021-09-30−¥53m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥157m
Reconciling Itemsreconcilingsegment profit2021-07-01 → 2021-09-30−¥82m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2021-04-01 → 2021-09-30¥1.7bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2021-07-01 → 2021-09-30¥877m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2021-04-01 → 2021-09-30¥1.6bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2021-07-01 → 2021-09-30¥847m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥56m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥29m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2021-04-01 → 2021-09-30¥163m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2021-07-01 → 2021-09-30¥113m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2021-04-01 → 2021-09-30¥5.8bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2021-07-01 → 2021-09-30¥3.1bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2021-04-01 → 2021-09-30¥5.8bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2021-07-01 → 2021-09-30¥3.0bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥31m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥23m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2021-04-01 → 2021-09-30¥1.7bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2021-07-01 → 2021-09-30¥877m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2021-04-01 → 2021-09-30¥2.1bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2021-07-01 → 2021-09-30¥1.1bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2021-04-01 → 2021-09-30¥2.1bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2021-07-01 → 2021-09-30¥1.1bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2021-04-01 → 2021-09-30¥730m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2021-07-01 → 2021-09-30¥400m
—segment totalrevenue2021-04-01 → 2021-09-30¥9.6bn
—segment totalrevenue2021-07-01 → 2021-09-30¥5.1bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥9.6bn
—segment totalrevenue external2021-07-01 → 2021-09-30¥5.0bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥88m
—segment totalrevenue intersegment2021-07-01 → 2021-09-30¥53m
—segment totalsegment profit2021-04-01 → 2021-09-30¥2.6bn
—segment totalsegment profit2021-07-01 → 2021-09-30¥1.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 883
ItemContextValueUnit
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E35308-000TeleMedicineReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E35308-000DispensingPharmacySupportReportableSegmentMember56000000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember88000000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-88000000JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E35308-000HealthcareBigDataReportableSegmentMember5829000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E35308-000TeleMedicineReportableSegmentMember2149000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E35308-000DispensingPharmacySupportReportableSegmentMember1659000000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember9639000000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-88000000JPY
Revenue IFRSPrior1YTDDuration9550000000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E35308-000HealthcareBigDataReportableSegmentMember1735000000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E35308-000TeleMedicineReportableSegmentMember730000000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E35308-000DispensingPharmacySupportReportableSegmentMember163000000JPY
Segment profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember2629000000JPY
Segment profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember-157000000JPY
Segment profit loss IFRSPrior1YTDDuration2472000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E35308-000HealthcareBigDataReportableSegmentMember7860000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E35308-000TeleMedicineReportableSegmentMember2439000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E35308-000DispensingPharmacySupportReportableSegmentMember1759000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReportableSegmentsMember12060000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSCurrentYTDDuration12060000000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E35308-000HealthcareBigDataReportableSegmentMember42000000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E35308-000TeleMedicineReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E35308-000DispensingPharmacySupportReportableSegmentMember84000000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember126000000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-126000000JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E35308-000HealthcareBigDataReportableSegmentMember7903000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E35308-000TeleMedicineReportableSegmentMember2439000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q2r_E35308-000DispensingPharmacySupportReportableSegmentMember1843000000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember12186000000JPY
Revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-126000000JPY
Revenue IFRSCurrentYTDDuration12060000000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E35308-000HealthcareBigDataReportableSegmentMember2028000000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E35308-000TeleMedicineReportableSegmentMember924000000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E35308-000DispensingPharmacySupportReportableSegmentMember192000000JPY
Segment profit loss IFRSCurrentYTDDuration_ReportableSegmentsMember3145000000JPY
Segment profit loss IFRSCurrentYTDDuration_ReconcilingItemsMember-189000000JPY
Segment profit loss IFRSCurrentYTDDuration2956000000JPY
Segment profit loss IFRSPrior1YTDDuration2472000000JPY
Segment profit loss IFRSCurrentYTDDuration2956000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration750000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration936000000JPY
Other income IFRSPrior1YTDDuration33000000JPY
Other income IFRSCurrentYTDDuration203000000JPY
Other expenses IFRSPrior1YTDDuration21000000JPY
Other expenses IFRSCurrentYTDDuration14000000JPY
Operating profit loss IFRSPrior1YTDDuration1733000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass